- Stocks
- Pharma & Healthcare
- Valiant Laboratories
Valiant Laboratories share price
NSE: VALIANTLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Valiant Laboratories at a glance
Valiant Laboratories (NSE: VALIANTLAB) closed at ₹131.05 on 22 Oct 2026, down 2.00% on the day. With a market capitalisation of ₹712 Cr, it ranks 1618th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −1.1% in FY26. Over the past year the share price has risen 56.4%. Its 52-week range is ₹49.51 (4 Mar 2026) to ₹141.38 (19 Oct 2026); the last close is 7.3% below the high. Promoters held 74.94% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹712 CrRank 1618 on NSE
- Price to book
- 0.9×FY26
- ROE
- −1.1%FY26
- ROCE
- 0.8%FY26
- Debt to equity
- 0.14FY26
- Net profit margin
- −1.4%FY26
- Book value / share
- ₹57.24FY26
- 52-week high
- ₹141.3819 Oct 2026
- 52-week low
- ₹49.514 Mar 2026
- 1-year return
- +56.4%
- RSI (14-day)
- 58.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.00% | +6.4% | +2.4% | +108.7% | +56.4% |
Valiant Laboratories financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹334 Cr | ₹182 Cr | ₹133 Cr | — |
| Operating profit | ₹38 Cr | −₹1 Cr | −₹2 Cr | — |
| Net profit | ₹29 Cr | ₹0 Cr | −₹2 Cr | — |
| EPS (₹) | ₹9.00 | ₹0.00 | −₹1.00 | — |
| Cash from operations | ₹56 Cr | ₹2 Cr | ₹1 Cr | — |
| Total debt | ₹59 Cr | ₹75 Cr | ₹104 Cr | ₹28 Cr |
| Shareholders' equity | ₹100 Cr | ₹237 Cr | ₹234 Cr | ₹311 Cr |
Valiant Laboratories shareholding pattern
| Holder | 30 Jun 2025 | 12 Aug 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| Foreign institutions | 0.63% | 0.52% | 0.02% | 0.01% | 0.20% | 0.00% |
| Domestic institutions | 0.46% | — | — | 0.00% | 0.00% | 0.00% |
| Non-institutions | 23.97% | 24.54% | 25.04% | 25.05% | 24.86% | 25.06% |
Valiant Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Valiant Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
| WANBURYWanbury | ₹185.66 | −0.42% | −25.7% | ₹649 Cr | 9.6 | — |
Ask anything about Valiant Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against VALIANTLAB's own history. Try: “Why has VALIANTLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on VALIANTLAB over five years” · “Compare VALIANTLAB with KILITCH on margins and valuation”
Frequently asked questions about Valiant Laboratories
What is the share price of Valiant Laboratories today?
Valiant Laboratories (NSE: VALIANTLAB) last closed at ₹131.05 on 22 Oct 2026. Its 52-week high is ₹141.38 and its 52-week low is ₹49.51.
What is the market cap of Valiant Laboratories?
Valiant Laboratories' market capitalisation is ₹712 Cr (₹712 Cr) at the 22 Oct 2026 close, ranking 1618th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Valiant Laboratories?
Return on equity was −1.1% in FY26 and return on capital employed was 0.8% in FY26 (consolidated figures).
Is Valiant Laboratories a debt-free company?
No. Valiant Laboratories' debt-to-equity ratio was 0.14 in FY26, with total debt of ₹28 Cr.
How has Valiant Laboratories stock performed over the last year?
Valiant Laboratories' share price has risen 56.4% over the past year, +108.7% over three months and +2.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Valiant Laboratories?
As of 30 Jun 2026: promoters 74.94%, foreign institutions 0.00%, domestic institutions 0.00%, non-institutions 25.06%.
Who are Valiant Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Valiant Laboratories by market cap are Kilitch Drugs (India), Vikram Thermo, Zim Laboratories, Amanta Healthcare, Gaudium IVF and Women Health and Wanbury.
Is Valiant Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Valiant Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VALIANTLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text